Regeneron scores Eylea patent win against Mylan, keeping biosimilar at bay
Regeneron prevailed in a major patent fight against Mylan, staving off biosimilar competition for its flagship eye drug Eylea for another few years.
The big …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
